![]() ![]() She will also work with College of Medicine researcher Otto Phanstiel, a medicinal chemist working on treatments for a variety of diseases including pancreatic cancer. She spent time in Masternak’s lab working on anti-aging research and participated in a recent NASA visit as part of UCF’s clinical research on the medical effects of human space travel. candidate from the University of Helsinki in Finland, who is spending four months doing research at UCF. “They learn from us and we learn from them,” he says. And because Europe has its own source of grant funding for medical research, the exchange helps UCF scientists find research partners abroad to develop projects with potential new funding opportunities. When his research team encountered a challenge in a gene targeting analysis, pharmaceutical researchers who had worked in the lab as part of the exchange offered advice based on their own technologies. First, academic and industry researchers have shared scientific technology and techniques, innovations and perspectives. Masternak says the partnership has brought multiple new opportunities. candidate from the University of Helsinki in Finland. UCF College of Medicine researcher Michal Masternak (left) works on antiaging research with Katia Sirna, a Ph.D. Participants from across the world will meet in Poland in July to report the results of their collaborations, including joint research projects and grants. “Orbis helps us share each other’s expertise.” Masternak’s lab at the Burnett Biomedical Sciences building in Lake Nona. “Working together helps us better address the different problems that take place in translational research,” she said during a recent meeting at Dr. Travel was halted during the pandemic and the war in Ukraine has kept participants from traveling to that country.īut despite the challenges, the partnership has successfully joined hundreds of academic researchers who do much of the basic science in medicine and pharmaceutical researchers at universities and industry focused on using that basic science to create tomorrow’s cures.īecause the two groups often work in isolation, they lose opportunities to streamline the research process to create discoveries faster, says Professor Janina Lulek, the program’s primary investigator. Funding pays for researchers to travel between Europe and the U.S. The European Union began Orbis in 2018 with an investment of $2.2 million Euros. “If you want to accomplish something in research, you can’t do it alone,” he says of the program. Masternak has had 13 European researchers working in his lab in the last 18 months. and has weathered a pandemic and a war to bring together professional, student and academic researchers for collaboration.Ĭollege of Medicine faculty researcher Michal Masternak and researchers from Rutgers University are the two U.S. It has participants from Poland, Ukraine, Germany, Finland, Ireland, the Czech Republic, Slovenia and the U.S. The Orbis (Open Research Biopharmaceutical Internships Support) project was created to address the scientific and economic challenges of bringing new drugs to market and was implemented under the European Union’s Horizon 2020 Marie Sklodowska-Curie-Research Innovation Staff Exchange. The combined company supports clients in 40 countries, including Fortune 500 companies, the military, and other government organizations.UCF is one of two American colleges participating in a European scientific exchange designed to bridge the gap between academic research and the development of tomorrow’s medical therapies. "Leveraging the Orbis RSuite CCMS platform allows us to not just create the content our clients require, but to also cost-effectively manage and publish that content." "Becoming a part of Orbis will allow us to bring new products and services to our clients, as well as leverage Orbis' global resources," said Scott Hartmann President and CEO of WAI. Minnesota-based WAI provides its clients with a wide variety of services, including technical and medical writing, Medicare and Medicaid proposal writing, copywriting, and courseware development. The WAI acquisition expands our presence in the healthcare industry and puts Orbis is a strong position to continue our rapid growth into 2023 and beyond." "WAI represents our third acquisition in the last twenty-four months and our largest acquisition to date. "With almost 30 years of experience, the acquisition of WAI strengthens our service offerings across various industries by adding over one hundred professional content developers to our service teams," stated Brian Ippolito, President and CEO of Orbis Technologies. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |